Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Retrospective Study of Ruxolitinib Rechallenge in chronic phase Myelofibrosis Patients

X
Trial Profile

A Retrospective Study of Ruxolitinib Rechallenge in chronic phase Myelofibrosis Patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RUX-MF
  • Most Recent Events

    • 17 Jun 2022 Results exploring prognostic correlation of myelodepletive phenotype (MyD) (ie, thrombocytopenia, leukopenia, anemia) phenotype in RUX-treated patients, presented at the 27th Congress of the European Haematology Association
    • 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 01 Apr 2021 Results (n=219) of subgroup analysis, evalauting Ruxolitinib rechallenge in chronic phase patients who received and stopped ruxolitinib for >14 days and survived for >30 days after discontinuation, published in the Cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top